Patients with Myelobrosis (MF) are considered fragile and thus eligible in Italy for COVID-19 BNT162b2 mRNA vaccination. According to the International Prognostic Scoring System (IPSS), patients with intermediate and high MF, may receive clinical benets from ruxolitinib, the rst approved JAK1/JAK2 inhibitor. Given the potent anti-in ammatory properties of ruxolitinib against immunocompetent cells, we previously reported a lower but non-statistically absolute IgG anti-Spike humoral response in vaccinated MF patients treated with ruxolitinib. In the present report we extended the cohort of MF patients.
Should be a Third Dose of BNT162b2 mRNA COVID-19-Vaccine Administered in Patients with Myelofibrosis Under Ruxolitinib?
Caocci, Giovanni
;Mulas, Olga;Costa, Alessandro;Galitzia, Andrea;Barabino, Luca;Greco, Marianna;La Nasa, Giorgio
2021-01-01
Abstract
Patients with Myelobrosis (MF) are considered fragile and thus eligible in Italy for COVID-19 BNT162b2 mRNA vaccination. According to the International Prognostic Scoring System (IPSS), patients with intermediate and high MF, may receive clinical benets from ruxolitinib, the rst approved JAK1/JAK2 inhibitor. Given the potent anti-in ammatory properties of ruxolitinib against immunocompetent cells, we previously reported a lower but non-statistically absolute IgG anti-Spike humoral response in vaccinated MF patients treated with ruxolitinib. In the present report we extended the cohort of MF patients.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
PDF 2 abstracts 1-s2.0-S0006497121045201-main.pdf
accesso aperto
Tipologia:
versione editoriale
Dimensione
389.59 kB
Formato
Adobe PDF
|
389.59 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
